Dolby Laboratories, Inc. DLB
NYSE · XNYS · stock · Patent Owners & Lessors
Chart by TradingView
6/9
Piotroski F — financial health
9.78
Altman Z″ — distress risk · safe
49.6%
Dividend payout · moderate
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.3B | $255.0M | $1.2B | $435.9M | $2.6B |
| 2024 | $1.3B | $261.8M | $1.1B | $297.2M | $2.5B |
| 2023 | $1.3B | $200.7M | $1.1B | $336.7M | $2.4B |
| 2022 | $1.3B | $184.1M | $1.1B | $270.6M | $2.3B |
| 2021 | $1.3B | $310.2M | $1.2B | $393.3M | $2.6B |
| 2020 | $1.2B | $231.4M | $1.0B | $277.5M | $2.4B |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 9.78 (safe)
- Working capital / assets 0.294
- Retained earnings / assets 0.816
- EBIT / assets 0.082
- Equity / liabilities 4.417
Source: SEC EDGAR filings · CIK 0001308547 · as of 2025-09-26. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.